Movano Health Q4 2022 net loss $7.9M; progressing toward summer 2023 Evie Ring launch

Corvex, Inc.

Net loss of $7.9M ($0.24/sh) in Q4 2022 vs $6.3M ($0.19/sh) in Q4 2021; no revenue in either period.
Cash and equivalents $10.8M at Dec 31, 2022; completed $7.5M public offering in Q1 2023.
Evie Ring on track for summer 2023 launch; second beta program with global athletic apparel and medical device firms.
Plan to file first 510(k) for heart rate and SpO2 clearance this spring after successful hypoxia trial (2% SpO2 margin of error).
Issued 9 new U.S. patents (21 total) for non-invasive blood pressure and glucose monitoring; first clinical studies imminent.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Corvex, Inc. reported the three months and year ending December 31, 2022 results: net income a net loss attributable to common stockholders of $7.9 million, or a loss of $(0.24) per basic and diluted share, in the, EPS net loss attributable to common stockholders of $30.3 million or $(0.92) per share, compared with a net loss attributabl.

Period: the three months and year ending December 31, 2022
Net income: a net loss attributable to common stockholders of $7.9 million, or a loss of $(0.24) per basic and diluted share, in the
EPS: net loss attributable to common stockholders of $30.3 million or $(0.92) per share, compared with a net loss attributabl
Result: reported results

Exact text from the filing

On March 20, 2023, Movano Inc. announced its financial results for the quarter and year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

Corvex, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-021242

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.